Skip to content
To the full analysis

GlaxoSmithKline Pharmaceuticals Stock: Key Metrics

GLAXO.NS
$29.43Closing price of 20 Nov 2026MEQIRI Score 74 out of 100

GlaxoSmithKline Pharmaceuticals had an operating margin of 33% and a return on invested capital (ROIC) of 39.1% in fiscal 2026.

Margins show how much of revenue is left over, returns on capital how hard the invested money works.

Daily figure as of 22 Nov 2026

Margins

  • Gross margin
  • Operating margin
  • Net margin
Figures as a table
YearGross marginOperating marginNet margin
200795.9%29.7%34.8%
200899.2%33.0%34.0%
2009102.7%33.5%34.9%
2010103.1%34.5%26.6%
2011103.9%35.2%26.1%
201292.4%32.8%17.8%
201386.4%30.1%21.2%
201472.2%20.3%18.9%
201553.5%33.6%14.4%
201667.7%17.2%14.0%
201762.6%13.5%11.6%
201869.7%17.0%12.5%
201971.3%18.0%14.4%
202071.3%15.0%2.9%
202153.8%17.9%12.4%
202255.6%21.4%no data
202357.9%23.2%18.9%
202458.7%24.4%17.1%
202560.5%29.9%24.9%
202643.6%33.0%27.1%

Returns on Capital

  • ROE
  • ROIC
  • ROA
Figures as a table
YearROEROICROA
200745.7%26.3%30.8%
200839.7%29.2%26.9%
200937.5%40.9%25.5%
201028.4%128.5%20.3%
201128.7%26.7%19.9%
201222.1%28.6%14.0%
201328.0%25.6%18.2%
201424.2%15.7%15.4%
201515.6%22.5%11.8%
201622.2%69.2%12.3%
201716.8%35.1%11.2%
201817.0%32.8%8.9%
201920.8%40.8%11.4%
20205.1%26.7%3.0%
202124.2%56.1%11.5%
2022no data14.7%no data
202335.1%21.6%18.4%
202433.2%29.8%16.6%
202547.5%38.7%22.6%
202645.7%39.1%24.0%
Buyback calculator for GlaxoSmithKline Pharmaceuticals

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Strong since 7 Nov 2026; valuation signal Overvalued since 22 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 20 Nov 2026 ($1 = ₹92.6752)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2026. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy